摘要号：4P

标题：Characteristics of DNA Copy Number Variations in Breast Cancer Nipple Discharge and Cellular Lineage Tracing【乳腺癌乳头溢液中DNA拷贝数变异特征与细胞谱系追踪】

讲者：Pengming Pu | 北京

摘要号：5P

标题：Pre- and post-diagnostic healthy lifestyle and long-term cardiovascular disease among breast cancer survivors【乳腺癌确诊前后健康生活方式与长期心血管疾病风险研究】

讲者：Qiang Liu | 天津

摘要号：7P

标题：Assessment of Overall Survival Outcomes in Elderly Patients with ER-Positive HER2-Negative Breast Cancer Following Adjuvant Chemotherapy: A Population-Based Cohort Study【辅助化疗后ER+/HER2-老年乳腺癌患者总生存期评估：一项基于人群的队列研究】

讲者：Wenjie Lv | 上海

摘要号：12P

标题：TIME-TNBC: A Landmark-Based Dynamic Prediction Model for Patients with Triple-Negative Breast Cancer【TIME-TNBC：一种基于界标法的三阴性乳腺癌患者动态预测模型】

讲者：Qingyao Shang | 北京

摘要号：14P

标题：Tracking Progress and Disparities in Breast Cancer MDT Implementation in China: Findings from a 2021–2025 National Survey【追踪中国乳腺癌多学科诊疗（MDT）实施进展与差异：基于2021-2025年全国调研的发现】

讲者：Bo Lan | 北京

摘要号：16P

标题：Dose Reduction in Neoadjuvant Chemotherapy: Outcomes and Safety in Comorbid Elderly-stage Breast Cancer Patients【新辅助化疗中的剂量降低：合并基础疾病的老年乳腺癌患者的生存结局与安全性】

讲者：Xiao Wang  | 上海

摘要号：19P

标题：Anthracycline-based Systemic Chemotherapy on the Long-Term Prognosis of Metaplastic Breast Cancer: A Real World Study with 637 case【蒽环类药物全身化疗对化生性乳腺癌长期预后的影响：一项包含637例患者的真实世界研究】

讲者：Peng Ni | 西安

摘要号：20P

标题：Interval Patterns and Prognostic Analysis of 440 Cases of Double Primary Breast and Lung Cancer：from a Single Center in Northeast China【440例乳腺-肺双原发癌的发病间隔模式与预后分析：基于中国东北地区单中心研究】

讲者：孙涛 | 辽宁省肿瘤医院

摘要号：32P

标题：Pegylated Liposomal Doxorubicin-Based Neoadjuvant Immunochemotherapy for Early-stage TNBC: A Taiwanese Multicenter Experience【基于聚乙二醇化脂质体阿霉素的新辅助免疫化疗用于早期三阴性乳腺癌（TNBC）：中国台湾地区多中心临床经验】

讲者：ChinYao Lin | 台湾

摘要号：35P

标题：Unmet needs and preference of Chinese HR+HER2- eBC patients across the treatment journey: Results from patient survey【中国HR+/HER2-早期乳腺癌患者在治疗过程中的未满足需求与偏好：患者调查结果】

讲者：殷咏梅 |  江苏省人民医院

摘要号：42eP

标题：Digital Twin Approach for AI-Based Prediction of Neoadjuvant Therapy Response in HER2-Positive Breast Cancer【基于数字孪生技术的人工智能模型预测HER2阳性乳腺癌新辅助治疗疗效】

讲者：Chih-Hsiang Chen | 台湾

摘要号：44eP

标题：Challenges and Opportunities in Multidisciplinary Team (MDT) Consultations for Breast Cancer Patients in Underdeveloped Areas in China: Insights from 46 Hospitals’ Feedback【中国欠发达地区乳腺癌患者多学科诊疗团队（MDT）会诊的挑战与机遇：基于46家医院反馈的观察】

讲者：Can Tian | 长沙

摘要号：45eP

标题：Comparison the clinical efficacy and safety of AT regimen and AT-NP regimen in the neoadjuvant treatment of HER2-negative breast cancer【AT方案相较于AT-NP方案用于HER2阴性乳腺癌新辅助治疗的临床疗效及安全性】

讲者：Xiaopei Dong | 北京

摘要号：46eP

标题：Research Advances in Patient-Reported Outcome Assessment Tools for Breast Cancer Patients【乳腺癌患者报告结局评估工具的研究进展】

讲者：Shen L. Li | 重庆

摘要号：50eP

标题：Predictive Value of Chemokine Profiles Combined with Polygenic Risk Score for Breast Cancer 【趋化因子谱联合多基因风险评分对乳腺癌的预测价值】

讲者：Jing Zheng | 福州

摘要号：51eP

标题：Genetic Susceptibility to Anxiety Independently Increases Breast Cancer Risk: MVMR Evidence【遗传易感性对焦虑的独立影响会增加乳腺癌风险：多变量孟德尔随机化证据】

讲者：Kang Ma | 广州

摘要号：52eP

标题：EZH2 inhibitors enhance the tumor microenvironment by inducing IL-12b secretion in breast cancer cells through NF-κB activation【EZH2抑制剂通过激活NF-κB诱导乳腺癌细胞分泌IL-12b，从而增强肿瘤微环境】

讲者：Peidong Yang | 南平

摘要号：57eP

标题：Reducing Diagnostic Delays for Neoadjuvant-Eligible Breast Cancer: A Fast-Track Pathology Model from a Chinese Tertiary Center【缩短新辅助治疗适用乳腺癌的诊断延迟：来自中国三级医疗中心的快速病理诊断模式】

讲者：Jing Zheng | 杭州

摘要号：69P

标题：Prognostic value and pathologic response rates of HER2-low status in breast cancer: a systematic review and meta-analysis【HER2低表达状态在乳腺癌中的预后价值及病理缓解率：一项系统性综述与荟萃分析】

讲者：Huacui Chen | 广州

摘要号：74P

标题：The Impact of Regional Nodal Irradiation for Patients with stage N1 breast cancer after breast-conserving surgery or mastectomy: A Systematic Review and Meta-analysis【区域淋巴结照射对N1期乳腺癌患者保乳术或乳房切除术后的影响：系统评价与荟萃分析】

讲者：Siran Yang | 深圳

摘要号：79eP

标题：Dietary structure influences breast cancer-associated lymphedema through the mediating effect of BMI【饮食结构通过体重指数（BMI）的中介作用影响乳腺癌相关淋巴水肿】

讲者：Yuzhi Yao | 广州

摘要号：81eP

标题：Mannan as the ligand of Dectin-2 reprograms macrophage metabolism through MALT1/STAT6/IL-4I1 axis to elicit trained immunity for anti-tumor therapy【甘露聚糖作为Dectin-2配体，通过MALT1/STAT6/IL-4I1轴重编程巨噬细胞代谢，诱导训练免疫以发挥抗肿瘤作用】

讲者：Li Chen | 北京

摘要号：82eP

标题：Targeting UCH37 Enhances MHC-I Antigen Presentation and Induces Immunogenic Cell Death in Triple Negative Breast Cancer【靶向UCH37增强三阴性乳腺癌中MHC-I抗原呈递并诱导免疫原性细胞死亡】

讲者：Qian Xiao | 重庆

摘要号：93P

标题：Efficacy and safety of mecapegfilgrastim for prophylaxis of dalpiciclib -induced neutropenia in patients with advanced HR+/HER2- breast cancer: a multicenter, open-label, randomized controlled phase II trial【硫培非格司亭预防HR+/HER2-晚期乳腺癌患者接受达尔西利治疗所致中性粒细胞减少的疗效与安全性：一项多中心、开放标签、随机对照II期试验】

讲者：Jieqiong Liu | 广州

摘要号：94P

标题：HKB99 Enhances Sensitivity of HER2-Positive Breast Cancer to Trastuzumab by Disrupting Bipolar Spindle Formation【HKB99通过破坏双极纺锤体形成来增强HER2+乳腺癌对曲妥珠单抗的敏感性】

讲者：Qian Li | 上海

摘要号：95P

标题：Pertuzumab versus Pyrotinib in combination with trastuzumab and taxanes for first-line(1L) treatment of patients with HER2–positive metastatic breast cancer (HER2+ MBC) : A multicenter real-world study【帕妥珠单抗对比吡咯替尼联合曲妥珠单抗与紫杉烷类药物一线治疗HER2阳性转移性乳腺癌（HER2+ MBC）：一项多中心真实世界研究】

讲者：Meiqiong K. Kuang | 北京

摘要号：96P

标题：Synergistic chemo-free regimen: A Phase II trial of immunoradiotherapy combined with PD-L1 inhibitor benmelstobart and anlotinib as a treatment for advanced HER2-negative breast cancer【协同无化疗方案：免疫放疗联合PD-L1抑制剂贝莫苏拜单抗和安罗替尼治疗晚期HER2-乳腺癌的II期试验】

讲者：Li Xie | 南京

摘要号：97P

标题：Analytical Validation of a Novel Super-ARMS PCR Assay for ESR1 Mutation Detection for Metastatic Breast Cancer Liquid Biopsy Sample【新型Super-ARMS PCR检测方法用于转移性乳腺癌液体活检样本ESR1突变检测的分析验证】

讲者：Jianqiang Fu | 厦门

摘要号：99P

标题：Construction of an Efficacy Prediction Model for T-DXd Treatment of HER2-Positive and HER2-Negative Breast Cancer Based on Hematological Indicators: A Multicenter retrospective Real-World Study【基于血液学指标构建的德曲妥珠单抗治疗HER2+和HER2-乳腺癌的疗效预测模型：一项多中心回顾性真实世界研究】

讲者：Yanfang Su | 北京

摘要号：100P

标题：A multicenter real-world study on survival analysis of pyrotinib in HER2-positive metastatic breast cancer【一项多中心真实世界研究中关于HER2+转移性乳腺癌患者使用吡咯替尼的生存分析】

讲者：Shiyi Li | 南京

摘要号：102P

标题：Patterns of Clinical Utilization and Outcomes of Abemaciclib (abema) Among Hormone Receptor+/Human Epidermal Receptor 2- (HR+/HER2-) Advanced Breast Cancer (ABC) Patients in China【阿贝西利在中国HR+/HER2-晚期乳腺癌（ABC）患者中的临床使用模式和结局】

讲者：Wenna Wang | 北京

摘要号：103P

标题：Prognosticating Axillary Lymph Node Metastasis in Breast Cancer through Integrated Photoacoustic Imaging, Ultrasound, and Clinical Parameters【通过综合光声成像、超声和临床参数预测乳腺癌腋窝淋巴结转移】

讲者：Zhibin Huang | 广州

摘要号：105P

标题：Causal Links Between Gut Microbiota Profiles and Breast Cancer Development via Immune Pathways【肠道菌群谱通过免疫通路与乳腺癌发生发展的因果关联】

讲者：Junnan Xu | 沈阳

摘要号：108P

标题：The Activity of SIM0270 Alone or in Combination with Everolimus or Palbociclib in ER-Positive, HER2-Negative Breast Cancer Patients with Brain Metastases【SIM0270单药或联合依维莫司/哌柏西利治疗ER+/HER2-脑转移乳腺癌患者的疗效】

讲者：孟艳春 | 复旦大学附属肿瘤医院

摘要号：109P

标题：Efficacy of Everolimus in Advanced Breast Cancer: A Real-World Study from a Single Institution【依维莫司在晚期乳腺癌中的疗效：一项单中心真实世界研究】

讲者：郝春芳 | 天津市肿瘤医院

摘要号：111P

标题：Efficacy and Safety of Post-CDK4/6 Inhibitor Treatment Options for HR-Positive, HER2-Negative Advanced Breast Cancer: A Network Meta-Analysis of Randomized Controlled Trials【后CDK4/6抑制剂时代HR+/HER2-晚期乳腺癌的治疗方案疗效与安全性：一项随机对照试验的网络荟萃分析】

讲者：Junxiao Wang | 福州

摘要号：112P

标题：Critical appraisal and assessment of bias among studies evaluating risk prediction models for breast cancer-related lymphatic metastasis: a systematic review【乳腺癌相关淋巴转移风险预测模型研究的偏倚评价与批判性分析：一项系统综述】

讲者：Lijuan Wang | 潍坊

摘要号：114P

标题：Characterizing Neurofibromin 1-altered Breast Cancer Through Genomic, Functional and Clinical Analyses【通过基因组、功能和临床分析描述神经纤维瘤病1型（NF1）突变乳腺癌的特征】

讲者：Xueyan Mao | 衡阳 

摘要号：116P

标题：Real-world outcomes with sacituzumab govitecan in treating Asian patients with advanced triple-negative breast cancer【戈沙妥珠单抗治疗亚洲晚期三阴性乳腺癌患者的真实世界结局】

讲者：Ming-Chun Kuo | 台湾高雄

摘要号：118P

标题：Mitoxantrone Hydrochloride Liposome (Lipo-MIT) combined with Capecitabine in HER2-negative advanced breast cancer: a dose-escalation, phase I study【盐酸米托蒽醌脂质体（Lipo-MIT）联合卡培他滨治疗HER2-晚期乳腺癌：一项剂量递增I期研究】

讲者：Qiao Li | 北京

备注：排名不分先后，按摘要号顺序排列；

官网信息持续更新中，详细信息请关注ESMO Asia官网；

如有遗漏或任何问题，请给我们留言~